$500,000 of EQUIFAX INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Government Benefit Eligibility Verification.
Issues related to H.R. 5775 - FCRA Liability Harmonization Act; Issues related to H.R. 5402/S. 1465 - Credit Access and Inclusion Act of 2025; Issues related to H.R. 8141 - Fair Credit Reporting Reseller Accuracy Act; Issues related to S. 619 - Credit Freeze for Kids Act; Issues related to the use of credit reports for mortgage; Issues related to eligibility verification.
General issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to defense appropriations.
Issues related to the Supplemental Nutrition Assistance Program; Issues related to P.L. 119-21; Issues related to eligibility verification.
Issues related to student loans.
Issues related to labor and unemployment insurance verifications.
Issues related to the Combat Methamphetamine Epidemic Act of 2005 (P.L. 109-177); Issues related to over-the-counter monographs.
Issues related to the Earned Income Tax Credit; Issues related to the Work Opportunity Tax Credit, including H.R. 1177/S. 492 - Improve and Enhance the Work Opportunity Tax Credit Act and H.R. 6321/S. 3265 - Improve and Enhance the Work Opportunity Tax Credit Act."
You can find more data on corporate lobbying on Quiver Quantitative.
EFX Congressional Stock Trading
Members of Congress have traded $EFX stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EFX stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
EFX Insider Trading Activity
EFX insiders have traded $EFX stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $EFX stock by insiders over the last 6 months:
- MARK W BEGOR (CEO) has made 0 purchases and 15 sales selling 75,582 shares for an estimated $14,144,730.
- JOHN W JR GAMBLE (EVP, CFO & COO) has made 0 purchases and 2 sales selling 8,000 shares for an estimated $1,498,630.
- JAMIL FARSHCHI (EVP, Chief Technology Officer) has made 0 purchases and 2 sales selling 7,380 shares for an estimated $1,449,815.
- CHAD M BORTON (EVP, Pres Workforce Solutions) sold 2,535 shares for an estimated $485,452
- CECILIA MAO (EVP, Chief Product Officer) purchased 2,400 shares for an estimated $464,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EFX Hedge Fund Activity
We have seen 386 institutional investors add shares of EFX stock to their portfolio, and 408 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOROBAN CAPITAL PARTNERS LP added 3,165,120 shares (+310.5%) to their portfolio in Q1 2026, for an estimated $560,827,612
- CAPITAL INTERNATIONAL INVESTORS removed 2,761,926 shares (-42.9%) from their portfolio in Q1 2026, for an estimated $489,385,667
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,599,598 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $283,432,769
- AQR CAPITAL MANAGEMENT LLC added 1,427,871 shares (+424.9%) to their portfolio in Q1 2026, for an estimated $253,004,462
- FMR LLC added 1,258,790 shares (+533.4%) to their portfolio in Q1 2026, for an estimated $223,045,000
- BROWN ADVISORY INC added 838,940 shares (+29.9%) to their portfolio in Q1 2026, for an estimated $148,651,778
- BRANDES INVESTMENT PARTNERS, LP added 747,201 shares (+inf%) to their portfolio in Q1 2026, for an estimated $132,396,545
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
EFX Price Targets
Multiple analysts have issued price targets for $EFX recently. We have seen 14 analysts offer price targets for $EFX in the last 6 months, with a median target of $221.0.
Here are some recent targets:
- Kevin Mcveigh from UBS set a target price of $220.0 on 07/08/2026
- Kyle Peterson from Needham set a target price of $265.0 on 07/07/2026
- Sean Kennedy from Mizuho set a target price of $210.0 on 07/02/2026
- Jason Haas from Wells Fargo set a target price of $220.0 on 06/18/2026
- Keith Mackey from RBC Capital set a target price of $32.0 on 05/28/2026
- Aaron Macneil from TD Cowen set a target price of $45.0 on 05/28/2026
- Curtis Nagle from B of A Securities set a target price of $225.0 on 05/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
Read full article here »
View the Zacks #1 Rank List
Lobbying Update: $500,000 of EQUIFAX INC lobbying was just disclosed
$500,000 of EQUIFAX INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Government Benefit Eligibility Verification. Issues related to H.R. 5775 - FCRA Liability Harmonization Act; Issues related to H.R. 5402/S. 1465 - Credit Access and Inclusion Act of 2025; Issues related to H.R. 8141 - Fair Credit Reporting Reseller Accuracy Act; Issues related to S. 619 - Credit Freeze for Kids Act; Issues related to the use of credit reports for mortgage; Issues related to eligibility verification. General issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027; Issues related to defense appropriations. Issues related to the Supplemental Nutrition Assistance Program; Issues related to P.L. 119-21; Issues related to eligibility verification. Issues related to student loans. Issues related to labor and unemployment insurance verifications. Issues related to the Combat Methamphetamine Epidemic Act of 2005 (P.L. 109-177); Issues related to over-the-counter monographs. Issues related to the Earned Income Tax Credit; Issues related to the Work Opportunity Tax Credit, including H.R. 1177/S. 492 - Improve and Enhance the Work Opportunity Tax Credit Act and H.R. 6321/S. 3265 - Improve and Enhance the Work Opportunity Tax Credit Act."
You can find more data on corporate lobbying on Quiver Quantitative.
EFX Congressional Stock Trading
Members of Congress have traded $EFX stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EFX stock by members of Congress over the last 6 months:
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
EFX Insider Trading Activity
EFX insiders have traded $EFX stock on the open market 21 times in the past 6 months. Of those trades, 1 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $EFX stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EFX Hedge Fund Activity
We have seen 386 institutional investors add shares of EFX stock to their portfolio, and 408 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
EFX Price Targets
Multiple analysts have issued price targets for $EFX recently. We have seen 14 analysts offer price targets for $EFX in the last 6 months, with a median target of $221.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
Read full article here »